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Abstract
Background: Recent studies have focused on the significant cytotoxicity of natural killer (NK) cells, cytokine-induced killer
(CIK) cells, and gamma-delta (γδ) T cells in tumor cells. Nevertheless, the therapeutic features of these cell types have not
been compared in the literature. The aim of this study was to evaluate the feasibility of activation and expansion of NK,
CIK, and γδ T cells from cancer patients in vitro, and to clarify the differences in their antitumor capacities.
Methods: NK, CIK, and γδ T cells were induced from the peripheral blood mononuclear cells of 20 cancer patients by using
specific cytokines. Expression of CD69, NKG2D, CD16, granzyme B, perforin, IFN-γ, and IL-2 was measured by flow cytometry.
Cytokine production and cytotoxicity were analyzed by enzyme-linked immunosorbent assay and Calcein-AM methods.
Results: NK cell proliferationwas superior to that of CIK cells, but lower than that of γδ T cells. NK cells had amuch stronger ability
to secrete perforin, granzyme B, IFN-γ, and IL-2 than did CIK and γδ T cells, and imparted significantly higher overall cytotoxicity.
Conclusions: ExpandedNK cells from cancer patients are themost effective immune cells in the context of cytokine secretion
and anti-tumor cytotoxicity in comparison to CIK and γδ T cells, making them an optimal candidate for adoptive
cellular immunotherapy.
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Background
Cellular immunity plays an essential role in anti-tumor
activity. Immunocyte activity is often compromised in
tumor patients, due to the inhibitory tumor environ-
ment. Therefore, numerous preliminary studies have
demonstrated the safety and efficacy of adoptive cellu-
lar immunotherapy (ACI)—consisting of ex vivo expan-
sion and activation of patient immunocytes followed by
reinfusion [1]. ACI has become a promising, innovative
strategy for personalized cancer therapy [2]. Due to the
complexity of immune escape—such as antigen loss,
MHC class I down-regulation, and the expression of in-
hibitory molecules—specific immune cells such as cyto-
toxic T lymphocytes (CTL) have limited utility in cancer
therapeutics [3]. Non-specific immune effector cells such as
natural killer (NK) cells, cytokine-induced killer (CIK) cells,
and gamma-delta (γδ) Tcells have better potential, since they
have noMHC restriction, contribute to front-line anti-tumor
surveillance, and bridge the gap between innate and adaptive
immunity [4, 5]. These cell types sharemany commonmech-
anisms, including NKG2D and perforin-mediated cytotox-
icity, and cytokine secretion [6–8]. However, each of them
has unique features, and their therapeutic effects have been
shown in ex vivo studies and clinical trials.
NK cells, which are large, granular CD3−CD56+ lympho-
cytes, can be rapidly activated to spontaneously attack certain
abnormal cells in the body, particularly cancerous or virus-
infected cells [9, 10]. Individuals who have lowNK cell activity
are at increased risk of developing cancer [11, 12]. Several clin-
ical trials have confirmed the therapeutic benefit and safety of
NK cell adoptive infusion [13, 14]. CIK cells are heteroge-
neous. The main effector cells are CD3+CD56+ Tcells, which
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exhibit both the powerful anti-tumor effect of T cells
and the non-MHC restriction of NK cells [15]. Recent
clinical studies have indicated that CIK cells can signifi-
cantly improve progression-free survival, overall survival,
and effective clinical response in cancer patients [16]. In
addition to NK and CIK cells, γδ T cells may display the
same cytotoxicity as NK and CIK cells, and act as antigen-
presenting cells.
For the past decade, ACI with NK, CIK, and γδ T cells
has been a primary focus in cancer therapy, especially
for hematological malignancies such as leukemia, lymph-
oma, and multiple myeloma [17–20]. However, there has
been no direct comparison of these cell types. In this
study, we evaluated the feasibility of in vitro expansion
of each immune cell type and compared their antitumor
activity against various forms of hematological cancers
with the aim of providing in vitro evidence for their use
in ACI cancer therapies.
Results
Cell quantification and expansion
NK, CIK, and γδ T cells were induced from the PBMCs
of 20 cancer patients. After 14 days induction, immuno-
cyte viability exceeded 85 % without contamination. All
cells were able to propagate in vitro: NK cells to a
median of 359-fold (250–669-fold, n = 20), CIK cells
to 253-fold (120–621-fold, n = 20), and γδ T to 550-fold
(159–879-fold, n = 20); γδ T cells had the strongest ampli-
fication ability (Fig. 1).
After induction and expansion, the percentage of ex-
panded NK (r = 0.339, p = 0.001), CIK (r = 0.358, p = 0.003),
and γδ T (r = 0.344, p = 0.004) cells showed a slight positive
correlation with their percentage in the patients’ blood
(Spearman’s test). These data suggest the percentage of
immune cells in the patients’ blood likely has little ef-
fect on the ex vivo induction of these immune cell
types, further demonstrating the stability and broad
applicability of our methods.
Immunophenotyping of expanded immune cells
The percentages of NK (CD56+CD3−), γδ T (Vγ9+CD3+),
and CIK (CD56+CD3+) cells before and after induction
were 16.1 (1.7–29.7) vs. 79.7 (62.1–98.4), 4.4 (0.9–10.2)
vs. 65.9 (40.2–98.2) and 12.7 % (1.6–21.1 %) vs. 35.4 %
(16.3–55.6 %), respectively. A portion of γδ T cells
(10.2–45.9 %) was CD56-positive, and nearly no expres-
sion of CD4 or CD8 was observed in the population.
However, the majority of CIK cells were CD8-positive
(Fig. 2).
NK and CIK cells in patient blood rarely express
CD69, but γδ T cells exhibited high expression of this
marker. After induction and expansion, activated NK
and CIK cells expressed much higher levels of CD69.
However, there was only a slight increase in CD69 ex-
pression on γδ T cells before and after induction. After
NKG2D induction, only γδ T cells showed a very strong
increase (Fig. 3a). However, CD16 expression differed
between immune cell types. NK cells had the highest
CD16 expression at 78.7 % (50.2–98.2 %). In contrast,
some of the CD3+CD56+ CIK cells (30.7, 6.9–59.6) and
γδ T cells (11.7 %, 2.6–37.7 %) were also CD16-positive
(Fig. 3b). After induction, inhibitory KIR CD158a and
CD158b on NK cells were down-regulated. Representative
results from one of these patients are shown in Fig. 3c.
All three induced immune cells expressed perforin.
NK cells showed much higher perforin production than
the other two expanded immune cell types. γδ T cells
showed slightly higher perforin production than CIK
cells (Fig. 4a). Almost all NK (97.3 ± 2.2) and CIK
(94.8 % ± 5.2 %) cells and a majority of γδ T cells
(72.3 % ± 13.1 %) were granzyme B-positive. However,
NK cells yielded the strongest expression of granzyme B
(Fig. 4b).
Cytokine secretion of the expanded cells
Nearly all of the expanded NK cells and half of the CIK
and γδ T cells were IFN-γ-positive. About 40 % of the
NK cells were IL-2-positive, while only a small portion
of CIK and γδ T cells were positive for IL-2 (Fig. 5a). NK
cells were much more efficient secretors of IFN-γ and
IL-2 than were CIK and γδ T cells (Fig. 5b). Subsets of
NK cells or CIK and γδ T cells secreted a very high level
of IFN-γ, yet only a small amount of IL-2 was detected
in the supernatant of the CIK and γδ T cells. No differ-
ences in INF-γ and IL-2 secretion were observed between
CIK and γδ T cells. Very low levels of IL-4, IL-6, and IL-
10 were detected in the supernatants of NK, CIK, and γδ
T cells (Fig. 4b).
Fig. 1 Fold expansion of NK, CIK, and γδ T cells. Fold expansion was
calculated by dividing the absolute output number of expanded NK,
CIK, and γδ T cells after 14 days of culture by the respective number
on day 0. Results are expressed as mean ± SD, n = 20; * p < 0.05,
** 0.001 < p < 0.01, *** p < 0.001
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Cytotoxicity of expanded immune cells against
hematologic malignancies cell lines
We compared the cytotoxicity of NK, CIK, and γδ T
cells against hematologic tumors, as bulk expanded im-
mune cells tested in the Calcein-AM assay showed
substantial cytotoxic capacity. NK cells exhibited the
most significant cytotoxicity in K562 (Fig. 6a), NB4
(Fig. 6b), HL-60 (Fig. 6d), and U266 (Fig. 6e) cells. Both
NK and γδ T cells produced stronger cytotoxic effects
against Jurkat cells than CIK cells (Fig. 6c). Although all
Fig. 2 The percentage of NK, CIK, and γδ T cells before and after induction. a The percentage of NK cells (CD3−CD56+) before and after induction.
b The percentage of γδ T (CD3+Vγ9+) and CIK (CD3+CD56+) cells before and after induction. γδ T and CIK cells were immunostained with CD4 and
CD8. Representative results from a single patient are shown
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three expanded cell types exhibited limited cytotoxicity
against Raji cells compared to other target cells, NK cells
exerted the strongest antitumor activity (Fig. 6f ). Inter-
estingly, the addition of rituximab significantly enhanced
Raji lysis by all cell types; however, NK cells continued
to show a greater synergistic cytotoxicity in Raji cells
with rituximab in comparison to CIK and γδ T cells.
Nevertheless, there were no notable differences in cyto-
toxicity against Raji cells between CIK and γδ T cells in
the presence of rituximab (Fig. 7).
Discussion
Although many studies have shown the importance of
NK, CIK, and γδ T cells in the prevention of tumor re-
lapse and metastasis in mice and humans [8, 21, 22], few
studies have directly compared their cytotoxic effects to
identify which would be the optimal candidate for clin-
ical application. There are many issues to be considered
prior to clinical application, including the number of in-
troduced cells, the feasibility of in vitro expansion, and
their respective anti-tumor activities.
Obtaining an adequate number of immune cells is a
key challenge for ACI application in a clinical setting
[23]. Studies indicate that sufficient numbers of CIK and
γδ T cells can be obtained by current methods [3, 20];
however, methods for the expansion of NK cells in vitro
have being investigated by using feeder cells, including
irradiated allogenic PBMCs [24], K562 cells [25], and
Epstein-Barr virus-transformed lymphoblastoid cell lines
[19]. Although these NK cell infusions are well tolerated
and partially effective, current methods for NK cell prep-
aration involve complex separation protocols and often
require ethical approval that render them expensive and
sub-optimal or unfeasible for large-scale clinical studies
[26]. To overcome these disadvantages, we examined
whether the use of CD16 antibody-coated flasks could
be used in place of feeder cells. Our studies demonstrate
that a substantial number of NK cells could be
generated, ranging from 250–669-fold expansions, after
14 days induction and culture. Importantly, this is com-
parable to the yields of feeder-cell methods [19]. In
addition to NK cells, we amplified CIK and γδ T cells in
Fig. 4 Perforin and granzyme B production in expanded NK, CIK, and γδ T cells. Three types of immune cells from twenty cancer patients were
harvested after 14 days induction in vitro. NK and CIK cells were stained with mAbs to CD3 and CD56, and γδ T cells were stained with CD3 and
Vγ9. After fixation and permeabilization, cells were stained for perforin and granzyme B using specific conjugated anti-human cytokine mAbs.
a Perforin-positive cells and mean fluorescence intensity (MFI) of NK, CIK, and γδ T cells. b Granzyme B-positive cells and MFI of NK, CIK, and γδ T
cells. Results are expressed as mean ± SD, n = 20. * p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001, ns p > 0.05
(See figure on previous page.)
Fig. 3 Expression of CD69, NKG2D, and KIR on induced immune cells. a The expression of CD69 and NKG2D were analyzed by flow cytometry (gray
histogram). CD69 and NKG2D expression peaks are shifted to the right in expanded cells versus pre-induction cells (black histogram). b Expression of
CD16; gray histograms depict isotype controls. c Expression of KIR (CD158a and CD158b) on NK cells before and after induction. Gray histograms depict
isotype controls and the black histogram depicts the specific antibody. Data from one representative patient is shown
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vitro using conventionally optimized methods. Although
several studies have shown that CIK cells easily prolifer-
ate in vitro [25], our investigation shows that the prolif-
erative ability of NK cells in our culture setup was
superior to that of CIK cells. We also found that the ra-
tios of NK, CIK, and γδ T cells in the blood of cancer
patients had no effect on their amplification efficiency.
These results demonstrate that all three expanded
immunocyte types have the potential for in vitro ex-
pansion to generate sufficient numbers for clinical
applications.
The antitumor capacity of effector cells is another
challenge in ACI. Our study assessed the phenotype,
cytokine production, and cytotoxicity of the expanded
cell types. Since NK, CIK, and γδ T cells have shown
significant efficacy in the treatment of hematological
Fig. 5 Cytokine production in NK, CIK, and γδ T cells. a Intracellular staining of IFN-γ and IL-2 in NK, CIK, and γδ T cells. Intracellular levels of IL-2
and IFN-γ were measured as described for perforin and granzyme B detection. b Extracellular cytokine production of NK, CIK, and γδ T cells. The
culture supernatants were collected and analyzed by ELISA for IFN-γ, IL-2, IL-4, IL-6, and IL-10. Results are expressed as the mean ± SD, n = 20. * p < 0.05,
** 0.001 < p < 0.01, *** p < 0.001, ns p > 0.05
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malignancies in vivo and in vitro, we selected leukemia
and multiple myeloma cell lines as target cells for our
analyses.
There are two main NK cell subsets distinguished by
the level of CD56 expression in human blood, namely
CD56dim and CD56 bright [27]. CD56dim cells are fully
matured and strongly express CD16, a low-affinity Fc
immunoglobulin G receptor that allows immune cells to
participate in ADCC [10]. In contrast, CD56bright cells
are more immature and are primarily considered to be
cytokine producers with a limited role in cytolytic re-
sponses [28]. The NK cells expanded in this study had
very high CD16 (Fig. 3b) and CD56 expression, and may
represent a subset of NK cells undergoing differenti-
ation. NK cells also express inhibitory and stimulatory
receptors, such as killer immunoglobulin-like receptor
(KIR), CD16, and NKG2D. The cytotoxic reactivity of
Fig. 6 Anti-tumor cytotoxicity of induced immune cells in vitro. Cytolysis against hematological malignancy targets K562 (a), NB-4 (b), Jurkat
(c), HL-60 (d), U266 (e), and Raji (f) cells were compared at 10:1 effector-target ratios (E:T). NK cells showed the most significant cytotoxicity.
Results are expressed as the mean ± SD, n = 20. * p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001, ns p > 0.05
Fig. 7 Antibody-dependent cellular cytotoxicity of induced NK, CIK,
and γδ T cells. Raji cells were pre-coated with rituximab (Genentech)
at 10 mg/mL for 30 min. The ADCC capacity at 10:1 effector-target
ratios (E:T) were measured by the calcein-AM method. Effector cells
were bulk samples of the cultured cells (i.e., no cell sorting was done).
Results are expressed as mean ± SD, n = 20. * p < 0.05, ** 0.001 <
p < 0.01, *** p < 0.001, ns p > 0.05
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NK cells results from the integration of signals from the
stimulatory and inhibitory receptors as they engage li-
gands on the target cell surface. Our studies show that
NK cells propagated in CD16 antibody-coated flasks ex-
hibit increased expression of NKG2D and CD69, and de-
creased expression of inhibitory KIR. Intracellular and
extracellular cytokine detection indicated that NK cells
were more potent producers of IFN-γ than CIK and γδ
T cells (Figs. 4a and 5e). IFN-γ enhances antigen presen-
tation by dendritic cells and stimulates production of the
CXC chemokines MIG (CXCL9) and IP-10 (CXCL-10),
which inhibit tumor angiogenesis and recruit CXCR3-
bearing effector cells to tumor sites [29, 30]. Therefore, NK
cells producing high amounts of IFN-γ could contribute
greatly to tumor regression during cancer immunotherapy.
Since induced immunocytes are usually used for ACI
without purification, these cultured cells were directly
harvested for cytotoxicity detection. In comparison to
CIK and γδ T cells, the NK cells expanded in this study
were significantly more cytotoxic toward many kinds of
malignant cells lines including NK-resistant Raji cells
(Fig. 6f ). Raji cells normally elude NK cell recognition
due to their expression of inhibitory KIR ligands (HLA-
Cw3 and HLA-Cw4) and a lack of NKG2D ligands
(MICA) [31, 32]. The increased cytotoxic effects ob-
served with our cultured NK cells likely result from their
down-regulation of inhibitory KIR–CD158a and CD158b
that engage HLA-Cw4 and HLA-Cw3, respectively.
ADCC is another mechanism by which cells convey
antitumor activity, which is dependent on immunocyte
CD16 expression. NK cells showed the highest expres-
sion of CD16 and the strongest ADCC efficacy in the
presence of rituximab (Fig. 7). This implies that large-
scale NK cell expansion can promote the development
of an effective combination therapy for cancer. While few
differences were observed in ADCC function between
CIK and γδ T cells, a significant difference in CD16 ex-
pression was detected between CD3+CD56+ CIK and γδ T
cells. Interestingly, CIK cells displayed a stronger cytotoxic
effect toward K562 and HL-60 cells than γδ T cells, in
contrast to our observations in Jurkat cells.
Conclusions
In this study, we established a cytokine-based expansion
system for NK cells with the aim of developing them for
clinical application. NK cells not only have a higher ex-
pansion capacity, but also much stronger antitumor ac-
tivity in cytokine production, director cytotoxicity, and
ADCC effect. Our analyses found that NK cells exhibit
stronger cytotoxicity against lymphoma, leukemia, and
myeloma cells than expanded CIK and γδ T cells. There-
fore, our study provides ex vivo evidence for the direct
comparison of NK, CIK, and γδ T cells. We also provide




Human leukemia (K562, HL-60, NB4, and Jurkat) cells,
multiple myeloma (U266) cells, and lymphoma (Raji)
cells were cultured in RPMI-1640 medium (Gibco, USA)
supplemented with 10 % heat-inactivated fetal bovine
serum (Gibco), 100 U/mL penicillin, and 100 mg/mL
streptomycin (Invitrogen, USA) at 37 °C in a humidified
5 % CO2 incubator.
Isolation of peripheral blood mononuclear cells
Heparinized peripheral blood samples were obtained
from 20 volunteer cancer patients. Blood samples were
centrifuged at 1800 × g for 10 min and plasma was trans-
ferred to new tubes. Peripheral blood mononuclear cells
(PBMCs) were isolated by density gradient centrifuga-
tion using Ficoll (Nycomed Pharma AS, Norway) at
800 × g for 30 min.
Expansion of NK, CIK, and γδ T cells
NK cells were expanded as described [33]. Briefly, PBMCs
were resuspended in AIM-V (Invitrogen) medium with
5 % auto-plasma, 500 U/mL IL-2, 2 ng/mL IL-15 (both
from Miltenyi Biotec, Germany), and 1 μg/mL OK432
(Shandong Luya Pharmaceutical Co., China) at a concen-
tration of 1 × 106 cells/mL. PBMCs were cultured in flasks
coated with anti-CD16 (Beckman, USA) for 24 h at 39 °C
in a humidified 5 % CO2 atmosphere. The cells were cul-
tured in AIM-V medium supplemented with 5 % auto-
plasma, 1000 U/mL IL-2, and 2 ng/mL IL-15 at 37 °C for
the next 13 days.
To generate CIK cells, PBMCs were cultured in AIM-V
medium with 5 % auto-plasma at 37 °C with 1000 U/mL
IFN-γ (Miltenyi Biotec). After 24 h, 100 ng/mL mouse
anti-human CD3 monoclonal antibody (Peprotech, USA),
1000 U/mL IL-2, and 1000 U/mL IL-1α (Miltenyi Biotec)
were added. Fresh complete medium and IL-2 supplement
(1000 U/mL) were added every three days.
To amplify γδ T cells, PBMCs were cultured in
complete medium with 1 μM zoledronate (Zoledronic
Acid, Jilin Province Xidian Pharmaceutical Sci-Tech
Development Co., China) and 400 U/mL human IL-2.
Fresh complete medium and IL-2 supplement (400 U/mL)
were added every 2 or 3 days.
Quantification
Cell expansion was expressed as “fold expansion,” which
was calculated by dividing the absolute output number
of NK, CIK, and γδ T cells after 14 days of culture by
their number on day 0. Absolute output numbers of
these three immune cells were calculated by multiplying
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the total number of viable cells by the percentages of
these three immune cells as determined by flow
cytometry. Total viable numbers of NK, CIK, and γδ
T cells were determined by the CASY cell counter
(BioSurplus, USA).
Immunophenotyping
The cultures were collected, washed, incubated for 15 min
with mouse mAbs against human CD3-PerCP, CD56-
FITC, or PE, CD69-APC, CD16-PE (BD Biosciences,
USA), and NKG2D-PE (BioLegend, USA). NK cells were
incubated with CD158a-PE and CD158b-PE (BD Phar-
mingen, USA), CIK cells were incubated with CD4-PE
and CD8-APC (BD Biosciences) and γδ T cells were incu-
bated with Vγ9-FITC (BD Pharmingen), CD4-PE, and
CD8-APC. Isotype-matched antibodies were used as con-
trols. Perforin and granzyme B detection was performed
according to the BD Cytofix/Cytoperm™ Kit manual (BD
Biosciences). Briefly, NK, CIK, and γδ T cells were har-
vested and adjusted to 1 × 106 cells/mL in RPMI-1640
medium containing 10 % fetal calf serum, and incubated
0.1 % GolgiStop (BD Biosciences) for 4 h. After pre-
incubation with 10 % normal human serum, cells were
stained with mAbs to identify NK (CD3−CD56+), CIK
(CD3+CD56+), and γδ T cells (CD3+Vγ9+), followed by
intracellular staining for perforin-PE and granzyme B-PE
(BD Pharmingen), and the corresponding isotype anti-
bodies to determine intracellular cytokine levels.
Flow cytometry data acquisition was performed on a
BD FACS Calibur (BD Biosciences) with Cell Quest Pro
software. Analysis was performed with FlowJo software
(Tree Star, USA).
Cytokine secretion analysis
NK, CIK, and γδ T cells were collected and suspended
(1 × 106 cells/mL) in AIM-V medium and incubated at
37 °C for 24 h in a humidified atmosphere of 5 % CO2.
Supernatants were collected for detection of IFN-γ, IL-2,
IL-4, IL-6, and IL-10. Cytokine secretion was quantified
using commercially available enzyme-linked immuno-
sorbent assay (ELISA) kits. Intracellular cytokine levels
of IL-2 and IFN-γ were measured as described above for
perforin and granzyme B.
Cytotoxicity analysis
NK, CIK, and γδ T cells were used as the effectors and
leukemia cells (K562, HL-60, NB-4, and Jurkat), lymph-
oma cells (Raji), and multiple myeloma cells (U266) were
used as targets. Briefly, target cells were collected,
washed once with PBS, and suspended in PBS at 1 × 106
cells/mL. Calcein-AM was added to a final concentra-
tion of 1 μM. Cells were incubated in a humidified at-
mosphere of 5 % CO2 for 30 min and then washed twice
with PBS. For antibody-dependent cellular cytotoxicity
(ADCC) assays, Raji cells were pre-coated with rituxi-
mab (Roche, Switzerland) at 10 mg/mL for 30 min.
Effector cells were bulk samples of the cultured cells,
i.e., no cell sorting was done. Lysis of the target cells
by effector cells was assessed by Calcein release assay
at a 10:1 effector-target ratio (E:T). After 4 h incubation,
calcein release in the supernatant was assessed on a Bio-
Tek Synergy HT Microplate Reader (BioTek Instruments,
USA). The percentage Calcein release was calculated ac-
cording to the formula: % specific release = [(experimental
release – spontaneous release)/(maximum release – spon-
taneous release)] × 100 %.
Statistical analysis
Flow cytometry data were collected before and after in-
duction and analyzed for correlation using Spearman’s
test. Other data were analyzed by Wilcoxon’s rank-sum
test in SPSS13.0 software. Results were considered sig-
nificant at p ≤ 0.05.
Informed consent/patient enrollment
In this study, 20 tumor patients were enrolled. In-
formed consent in accordance with the Declaration of
Helsinki was obtained from all patients, and approval
was obtained from the Ethics Committee of the the
First Hospital of Jilin University (protocol #2010–019).
Table 1 Clinicla data of the patients in the study
Patients no. Gender Age Type of tumor Stages of disease
1 Female 36 Gastric Cancer IB(T2N0M0)
2 Male 65 Gastric Cancer IV(T4bN0M1)
3 Male 80 Gastric Cancer IV (rcTxNxM1)
4 Female 71 Gastric Cancer IIA (T3N0M0)
5 Female 39 Gastric Cancer IIB (T1bN3aM0)
6 Male 66 Kidney Cancer (T1aNxMx)
7 Male 62 Kidney Cancer (T4NxM0)
8 Female 59 Breast Cancer IV (pT1N1M1)
9 Female 49 Breast Cancer I (pT1N0M0)
10 Female 49 Breast Cancer I (pT1cN0M0)
11 Female 56 Breast Cancer I (pT1N0M0)
12 Male 61 Liver Cancer C (BCLC)
13 Male 71 Liver Cancer IV (Intrahepatic
cholangiocellular
carcinoma)
14 Male 80 Liver Cancer Early A (BCLC)
15 Female 63 Lung Cancer IB (pT2aN0M0)
16 Male 50 Lung Cancer IIIA (pT2aN2M0)
17 Male 43 Lung Cancer IB (pT2N0M0)
18 Male 68 Lung Cancer IIB (pT3N0M0)
19 Female 56 Lung Cancer (pTisN0M0)
20 Female 69 Lung Cancer Extended stage
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Inclusion criteria were no radiation or chemotherapy
for at least one month before blood collection. Only pa-
tients with solid tumors were included. Patient charac-
teristics are listed in the Table 1.
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